SANUWAVE will host a conference call to present Q3 2023 financial results on November 10, 2023 at 8:00 AM (ET)

EDEN PRAIRIE, Minn., November 8, 2023 (GLOBE NEWSWIRE) — through NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, will host a live conference call to present its third quarter 2023 financial results on Friday, November 10, 2023 at 8:00 AM (ET).

Telephone access to the conversation is possible by calling the following numbers:

Participant Listen: 1-877-407-0784 or 1-201-689-8560

Conference ID number: 13742652

OR click on the Call me™ link for direct telephone access to the event.
https://callme.viavid.com/viavid/?callme=true&passcode=13732361&h=true&info=company&r=true&B=6

Attendees can use the Guest dial-in numbers above and be answered by an operator OR click on the Call me™ link for direct telephone access to the event.

A replay is available until November 24, 2023:

Replay dial-in: 1-844-512-2921 or 1-412-317-6671

Access ID: 13742652

About SANUWAVE
SANUWAVE Health focuses on the research, development and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.

SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic and cardiac/endovascular conditions.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding financial results and plans for future business development activities, and are therefore forward-looking. Forward-looking statements include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s control. Actual results may differ materially from those projected in the forward-looking statements. Key risks, assumptions and factors that could affect the company’s results of operations, performance and financial condition include risks associated with the approval and marketing of the Company’s product candidates and products. [unproven pre-clinical] and clinical development activities, regulatory oversight, the Company’s ability to manage its capital issues, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

CONTACT:
Investors@Sanuwave.com